AIkido Pharma Inc. (AIKI) News
Filter AIKI News Items
AIKI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AIKI News Highlights
- AIKI's 30 day story count now stands at 2.
- Over the past 6 days, the trend for AIKI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest AIKI News From Around the Web
Below are the latest news stories about AIKIDO PHARMA INC that investors may wish to consider to help them evaluate AIKI as an investment opportunity.
Dominari Holdings Provides Update on Share Repurchase ProgramDominari Holdings Inc. (Nasdaq: DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. |
AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)AIkido Pharma Inc. (NASDAQ: AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. |
AIkido Pharma Announces Successful Initial Public Offering of ASP IsotopesAIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. |
AIkido Pharma (AIKI) Gets a Buy from H.C. WainwrightIn a report released today, Vernon Bernardino from H.C. Wainwright maintained a Buy rating on AIkido Pharma (AIKI - Research Report), with a price target of $16.00. The company's shares opened today at $4.30.Bernardino covers the Healthcare sector, focusing on stocks such as Geron, Artelo Biosciences, and Cassava Sciences. According to TipRanks, Bernardino has an average return of 19.4% and a 32.49% success rate on recommended stocks. AIkido Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $13.90 and a one-year low of $4.14. |
AIkido Share Repurchase ContinuesAIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. |
AIkido Purchases More SharesAIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. |
Share Repurchase Program ContinuesAIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. |
AIkido Pharma Continues Share Repurchase ProgramAIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. |
AIkido Pharma Provides Update on Share Repurchase ProgramAIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022. |
Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-DealerDominari Financial, Inc., the financial services subsidiary of AIkido Pharma Inc., (NASDAQ: AIKI) has entered into an exclusive agreement for the acquisition of a broker-dealer firm. This is Dominari's first acquisition since launching in June. Details of the proposed purchase can be found in the 8K on file with the SEC. |